Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Total Equity: NT$285.1 Mil (As of Dec. 2025)


ROCO:4186 Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
52 GF Score
Price NT$10.05
GF Value NT$17.90
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Taiwan Advance Bio-Pharmaceutical Total Equity?

Taiwan Advance Bio-Pharmaceutical ROCO:4186 52 Total Equity is NT$285.1 Mil as of Dec. 2025. GuruFocus rates ROCO:4186 with a GF Score™ of 52/100 and a GF Value™ of NT$17.90 (Possible Value Trap). The stock has 4 warning signs investors should review.

Taiwan Advance Bio-Pharmaceutical's total equity for the quarter that ended in Dec. 2025 was NT$285.1 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Taiwan Advance Bio-Pharmaceutical Total Equity Historical Data

* Premium members only.

The historical data trend for Taiwan Advance Bio-Pharmaceutical's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Taiwan Advance Bio-Pharmaceutical Total Equity Chart

Taiwan Advance Bio-Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 241.45 244.64 233.92 256.44 285.10

Taiwan Advance Bio-Pharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.92 228.81 256.44 252.55 285.10
ROCO:4186
52GF Score
Taiwan Advance Bio-Pharmaceutical Inc ROCO:4186
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taiwan Advance Bio-Pharmaceutical Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Taiwan Advance Bio-Pharmaceutical's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=746.739-461.642
=285.1

Taiwan Advance Bio-Pharmaceutical's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=746.739-461.642
=285.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$285.1 Mil mean?
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a Total Equity of NT$285.1 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Taiwan Advance Bio-Pharmaceutical and its competitors.
Is Taiwan Advance Bio-Pharmaceutical's Total Equity too high?
Taiwan Advance Bio-Pharmaceutical's current Total Equity is NT$285.1 Mil. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's Total Equity compare to VRTX and REGN?
Taiwan Advance Bio-Pharmaceutical's Total Equity of NT$285.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Taiwan Advance Bio-Pharmaceutical and its competitors. Taiwan Advance Bio-Pharmaceutical's current Total Equity is NT$285.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.90, compared to a current price of NT$10.05 — trading 43.9% below its estimated fair value. The current Total Equity is NT$285.1 Mil. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current Total Equity is NT$285.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?

Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued. The current stock price of NT$10.05 is trading 43.9% below its estimated GF Value™ of NT$17.90. GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:4186:

  • Total Equity: NT$285.1 Mil
  • GF Value™: NT$17.90 vs. price of NT$10.05 (43.9% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Taiwan Advance Bio-Pharmaceutical Business Description

Address No. 363, Section 2, Fuxing South Road, 5th Floor, Daan District, New Taipei City, TWN, 22180
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
52GF Score

Get the complete analysis for ROCO:4186

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.05
Price
NT$17.90
GF Value